drugset / Trial / NCT00189319

To Evaluate the Impact of Oral Flecainide on Quality of Life in Patients With Paroxysmal Atrial Fibrillation

NCT00189319

Phase 4 Completed 200 enrolled MEDA Pharma GmbH & Co. KG
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the management of paroxysmal atrial fibrillation with controlled release flecainide on patient's quality of life.

Timeline

Start
2003-09
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject flecainide Small molecule